Fabrication of Electrospun Levodopa-Carbidopa Fixed-Dose Combinations

Bukhary, Haitham A.; Williams, Gareth R.; Orlu, Mine

doi:10.1007/s42765-020-00031-1

Cited by 23 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to both drugs having similar initial concentrations (0.5% w / v ) and similar core and shell flow rates (0.5 mL/h), the resultant DL and EE were almost equivalent. This high EE% of > 85% was also obtained in the coaxial fiber systems of [ 40 , 60 ].…”

Section: Resultssupporting

confidence: 66%

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder

et al. 2021

Self Cite

View full text Add to dashboard Cite

Major depressive disorder (MMD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD fail to achieve response or remission leading to treatment-resistant depression (TRD). One of the psychopharmacological strategies to overcome TRD is using a combination of an antipsychotic as an augmenting agent with selective serotonin reuptake inhibitors (SSRIs). Among which, an atypical antipsychotic, quetiapine (QUE), and an SSRI, escitalopram (ESC), were formulated as a fixed-dose combination as a fast-dissolving film by coaxial electrospinning. The resultant fiber’s morphology was studied. SEM images showed that the drug-loaded fibers were smooth, un-beaded, and non-porous with a fiber diameter of 0.9 ± 0.1 µm, while the TEM images illustrated the distinctive layers of the core and shell, confirming the successful preparation of these fibers. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies confirmed that both drugs were amorphously distributed within the drug-loaded fibers. The drug-loaded fibers exhibited a disintegration time of 2 s, which accelerated the release of both drugs (50% after 5 min) making it an attractive formulation for oral mucosal delivery. The ex vivo permeability study demonstrated that QUE was permeated through the buccal membrane, but not ESC that might be hindered by the buccal epithelium and the intercellular lipids. Overall, the developed coaxial fibers could be a potential buccal dosage form that could be attributed to higher acceptability and adherence among vulnerable patients, particularly mentally ill patients.

show abstract

Section: Resultssupporting

confidence: 66%

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The casting films often have a solid inner structure, which determines that the encapsulated drug molecules have a long way to diffuse for dissolution, and thus, a fine sustained release profile is achieved accordingly [ 50 , 51 ]. The drug sustained release profiles not only benefit the patients with reduced administration times being ensured, but also can keep a constant blood drug concentration, and thus, a safer therapeutic effect [ 52 , 53 , 54 ].…”

Section: Introductionmentioning

confidence: 99%

Hybrid Films Prepared from a Combination of Electrospinning and Casting for Offering a Dual-Phase Drug Release

et al. 2022

View full text Add to dashboard Cite

One of the most important trends in developments in electrospinning is to combine itself with traditional materials production and transformation methods to take advantage of the unique properties of nanofibers. In this research, the single-fluid blending electrospinning process was combined with the casting film method to fabricate a medicated double-layer hybrid to provide a dual-phase drug controlled release profile, with ibuprofen (IBU) as a common model of a poorly water-soluble drug and ethyl cellulose (EC) and polyvinylpyrrolidone (PVP) K60 as the polymeric excipients. Electrospun medicated IBU-PVP nanofibers (F7), casting IBU-EC films (F8) and the double-layer hybrid films (DHFs, F9) with one layer of electrospun nanofibers containing IBU and PVP and the other layer of casting films containing IBU, EC and PVP, were prepared successfully. The SEM assessments demonstrated that F7 were in linear morphologies without beads or spindles, F8 were solid films, and F9 were composed of one porous fibrous layer and one solid layer. XRD and FTIR results verified that both EC and PVP were compatible with IBU. In vitro dissolution tests indicated that F7 were able to provide a pulsatile IBU release, F8 offered a typical drug sustained release, whereas F9 were able to exhibit a dual-phase controlled release with 40.3 ± 5.1% in the first phase for a pulsatile manner and the residues were released in an extended manner in the second phase. The DHFs from a combination of electrospinning and the casting method pave a new way for developing novel functional materials.

show abstract

“…The O-H stresses at 2980 cm −1 , phenyl group C=C vibrations at 1455, 1404, 1352, 817, and 674 cm −1 , the phenyl group C=C vibrations at 1458, 1404, 817 and 674 cm −1 , and C-H at 2929 and 2982 cm −1 for pure levodopa are shown in Figure 2c. Furthermore, the NH2 stresses are observed at 1562 cm −1 and C=O stresses are observed at 1651 cm −1 [29]. Figure 2 shows that the characteristic peaks of PLA, CS, and levodopa were obtained in pure and levodopa-loaded PLA/CS scaffolds.…”

Section: Fourier Transform-infrared Spectroscopy (Ft-ir)mentioning

confidence: 93%

Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson’s Disease

et al. 2021

View full text Add to dashboard Cite

Parkinson’s disease, the second most common neurodegenerative disease in the world, develops due to decreased dopamine levels in the basal ganglia. Levodopa, a dopamine precursor used in the treatment of Parkinson’s disease, can be used as a drug delivery system. This study presents an approach to the use of 3D-printed levodopa-loaded neural tissue scaffolds produced with polylactic acid (PLA) and chitosan (CS) for the treatment of Parkinson’s disease. Surface morphology and pore sizes were examined by scanning electron microscopy (SEM). Average pore sizes of 100–200 µm were found to be ideal for tissue engineering scaffolds, allowing cell penetration but not drastically altering the mechanical properties. It was observed that the swelling and weight loss behaviors of the scaffolds increased after the addition of CS to the PLA. Levodopa was released from the 3D-printed scaffolds in a controlled manner for 14 days, according to a Fickian diffusion mechanism. Mesenchymal stem cells (hAD-MSCs) derived from human adipose tissue were used in MTT analysis, fluorescence microscopy and SEM studies and confirmed adequate biocompatibility. Overall, the obtained results show that PLA/CS 3D-printed scaffolds have an alternative use for the levodopa delivery system for Parkinson’s disease in neural tissue engineering applications.

show abstract

Fabrication of Electrospun Levodopa-Carbidopa Fixed-Dose Combinations

Cited by 23 publications

References 37 publications

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder

Hybrid Films Prepared from a Combination of Electrospinning and Casting for Offering a Dual-Phase Drug Release

Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson’s Disease

Contact Info

Product

Resources

About